Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
about
Other targeted drugs in melanomaMultikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinibGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsFunctional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersThe 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognitionDesign, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffoldFGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell CancersFibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.Toward precision medicine of breast cancerInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationPhase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsEmergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumoursConformational transition of FGFR kinase activation revealed by site-specific unnatural amino acid reporter and single molecule FRET.Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells.Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaDiscovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis.A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signalingRecurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.The FGF/FGFR axis as a therapeutic target in breast cancer.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitorsMolecularly targeted therapies in non-small-cell lung cancer annual update 2014The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Combinatorial Pharmacophore-Based 3D-QSAR Analysis and Virtual Screening of FGFR1 Inhibitors.CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activitiesRasGAP Shields Akt from Deactivating Phosphatases in Fibroblast Growth Factor Signaling but Loses This Ability Once Cleaved by Caspase-3.Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical developmentFibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma.Targeting tumor metastases: Drug delivery mechanisms and technologies.Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer.Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.FGF19 functions as autocrine growth factor for hepatoblastomaFGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell CarcinomaFGFR fusions in the driver's seatTrichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo
P2860
Q26775594-B4FCC403-E00D-43FE-BBF3-349062830E9FQ26821959-A01C6F65-F253-4F14-84C8-23100805C4DDQ26998790-BAD51A7B-EFCB-4C67-A178-1D891E905ABEQ26998955-2574E248-44D5-4AAB-B5FD-EFB2AA7EAF31Q27698320-25AD1C56-E8BF-4E14-AADF-619F11AB7058Q27701029-1C5B203D-FECA-4FE4-BA84-CA39DD14FA47Q27853171-4E4E16A9-AD04-4D83-A6B0-19122026E20EQ27853178-E31E14D5-E9A8-493D-9B21-49691B448456Q28073967-0D424C25-5F2A-40E9-B72F-300FAB95EEABQ28079309-A536058B-26BC-4D9D-9CE2-5B24A55F23BFQ28247372-82E37723-2887-4C7A-AFD7-A0DCFDB068DAQ28609639-72DD51D3-E352-4818-8F4D-BC0118A1CF5DQ30833549-F0BAC922-1942-4530-BBFA-2340015CFE9EQ33586758-CE87F733-70B8-42B5-9A87-4D3FEA19D7B4Q33634701-DEF36126-CCE2-46E8-BEFA-045D42542FD4Q33742954-57B0CC62-9888-4021-ABFD-42EF27F7CF6FQ33888883-1AAE85DD-D164-4F34-A1FD-AD971A0F9D2CQ34101045-3D4BAFF9-1316-408F-8514-52DBD1D580DDQ34218313-732BB7C8-175D-42F7-85F6-C98AC4961288Q34287704-1887F71C-E170-4F8C-AD5D-EB97E95A4165Q34354839-FCAF755A-D2D5-45D0-BF09-6F98945016E5Q34495216-CD07245F-8439-46D9-8A75-E3305CE79BABQ34525925-F844414A-C4FF-4017-A187-9E33A49383CAQ34619293-CECA074E-645A-4D61-98DF-0462BF7964B2Q35051588-CFBF2EC4-E2A1-437E-A089-56204E60BC12Q35136424-80D7BD01-E7A5-4C40-B9D0-74296D678819Q35752926-E313EC1A-2D62-425F-9E25-935C0B059580Q35814029-64A7B860-4439-4003-9922-21BE6FB722CEQ35828490-58B21E08-1D5D-41AF-ABFE-4BAB218B4AD3Q35925830-01C0FDA8-D63E-4A71-822F-9C050353FCA3Q35965295-FD54F2F5-9976-4C0F-B52F-934AF1428EF3Q36299617-9C48644E-219F-4FD1-A83A-94915EC5F692Q36528389-2F06402D-3C97-4064-8B58-4095BB29DD9CQ36557855-C390F33E-FDF5-4611-9817-1C8300B0F23EQ36859396-E8EF218B-C313-4EC0-9152-200A683F0638Q36967528-C05DF6B9-81B6-4E41-926A-B5E24BD81E2EQ37033310-07075A88-5580-4572-BD22-636B6C5015A9Q37067161-CA3853A5-A0B7-44C3-9697-2E6D750E96A7Q37183489-F9DB7865-D190-4EE3-9579-04116FC1A3DBQ37295668-F3B60B20-8122-4893-A408-3B78FBF20AE7
P2860
Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Fibroblast growth factor recep ...... onale to medical perspectives.
@en
type
label
Fibroblast growth factor recep ...... onale to medical perspectives.
@en
prefLabel
Fibroblast growth factor recep ...... onale to medical perspectives.
@en
P2093
P1433
P1476
Fibroblast growth factor recep ...... onale to medical perspectives.
@en
P2093
Fabrice Andre
Jean Charles Soria
Monica Arnedos
P304
P356
10.1158/2159-8290.CD-12-0362
P577
2013-02-15T00:00:00Z